PT Soho Global Health Tbk

soho

Overview

SOHO Overview

PT Soho Global Health Tbk is an Indonesia-based company. The Company operates in the healthcare sector. The Company operates through five segments: Distribution, Professional product, Consumer health, Alliance, and Others. Its brands include Curcuma Plus, Curcuma Plus Milk, Imboost, Fitkom, Diapet, Laxing, Lelap, Asthma Soho and Sohobion. Curcuma Plus is a kid’s multivitamin that contains curcuma and fish oil. Curcuma Plus Milk is a growing up milk for kids. Imboost is a supplement that supports immune system. Fitkom offers kids multivitamins in gummy and tablet format. Diapet is an anti-diarrheal medicine. Laxing is a medicine for healthy digestion and bowel movement. Lelap is a medicine to alleviate sleep disorders. Asthma Soho is an asthma remedy. Sohobion is a neurotropic vitamin supplement to maintain neurological health. The Company's product portfolio ranged from wound care, hospital general care, surgery, orthopedics, and in-vitro diagnostics.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: SOHO

Watchlist
Market Cap.
IDR 6.24Trillion

~$397.41M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

SOHO Valuation Metrics

492

IDR

Closing Price on 2024-04-05

Price to Equity

18.42

P/E

At 18.42x P/E TTM, SOHO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 8.9x).

Price to Book

2.45

P/B

At 2.45x P/B TTM, SOHO.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.3x).

Price to Sales

0.79

P/S

At 0.79x P/S TTM, SOHO.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Soho Global Health Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Soho Global Health Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
132.02x
Price/Forward Earnings
-
Enterprise Value/Revenue
0.71x
Enterprise Value/EBITDA
11.79x
PEG Ratio
0.79x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of SOHO stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 18.42x is above the ID market average of 8.22x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (8.87x).
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 2.45x is above the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector. SOHO trades at a higher P/B ratio than >75% of its peers in the Pharmaceuticals & Health Care Research sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.79x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of SOHO's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. SOHO's P/CF ratio of 132.02x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. SOHO's EV/R ratio of 0.71x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x. ●●●
Max 3

Peers

SOHO Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of SOHO stock
WeightNotesScore
High
At a market cap of IDR 6,244.32 billion, SOHO.JK ranks 9 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of 18.42, SOHO.JK ranks 8 out of 10 companies in the Healthcare sector for P/E value. The average PE is -17.68 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 18.42, SOHO.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). false●●
Max 2
Medium
At a revenue of IDR 7.91 trillion, SOHO.JK ranks 4 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of IDR 0.34 trillion, SOHO.JK ranks 7 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of SOHO

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for SOHO at the moment.
Future growth prospect of SOHO
WeightNotesScore
High
SOHO's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for SOHO's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
SOHO and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for SOHO's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Rogelio Paulino Jr. Castillo La O15.2 years
Piero Brambati
Director
Yuliana
Director
Henryk Klakurka
Director
Tan Ting Luen
Director
Wonbae Lee
Director
NamePositionShares%
No data is available for SOHO at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

SOHO Ownership

Others
4.09%
Insiders
95.91%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Tiberias 96 Pty Ltd4,812,370,31037.922,367.69B
Medisia Investment Holdings Pte. Ltd.2,851,733,00022.471,403.05B
Cascade Creek Pty Ltd1,537,362,00012.11756.38B
Fraburg Pty Limited1,202,423,9109.47591.59B
Tan Giok Nio1,143,986,1709.01562.84B
Prysselius Limited624,206,7004.92307.11B
Public (Scripless)519,600,3004.09255.64B
No data is available for SOHO at the moment.